Medicxi Ventures Management

Latest statistics and disclosures from Medicxi Ventures Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHAT, NAMS, AURA, and represent 100.00% of Medicxi Ventures Management's stock portfolio.
  • Reduced shares in these 2 stocks: Centessa Pharmaceuticals (-$793M), NAMS (-$16M).
  • Sold out of its position in Centessa Pharmaceuticals.
  • Medicxi Ventures Management was a net seller of stock by $-809M.
  • Medicxi Ventures Management has $177M in assets under management (AUM), dropping by -81.93%.
  • Central Index Key (CIK): 0001715579

Tip: Access up to 7 years of quarterly data

Positions held by Medicxi Ventures Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Medicxi Ventures Management

Medicxi Ventures Management holds 3 positions in its portfolio as reported in the June 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Phathom Pharmaceuticals (PHAT) 45.6 $81M 7.5M 10.85
 View chart
Newamsterdam Pharma Company Ordinary Shares (NAMS) 42.2 $75M -17% 2.2M 33.89
 View chart
Aura Biosciences (AURA) 12.2 $22M 3.0M 7.10
 View chart

Past Filings by Medicxi Ventures Management

SEC 13F filings are viewable for Medicxi Ventures Management going back to 2019

View all past filings